PLx Pharma Inc. PLXP Cash Flow

Plx pharma inc. (PLXP)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)
1,496	-2,000	1,703	-9,347	-10,858	2,946	-3,425	-3,603	4,978	-7,884	-3,799	-2,236	-1,426	-1,453	-1,082	3,447	-5,816	-5,504	-5,019	-4,031	-4,187	-3,273	-3,843	-3,920	-2,543	-2,252	-990	-363	-406
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization
31	31	31	39	55	55	55	55	34	17	9	2	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation
272	272	260	276	66	76	247	236	281	276	957	203	187	668	571	-120	1,353	544	544	544	1,643	446	417	458	95	716	137	127	96
Amortization of debt discounts and issuance costs
34	42	50	58	63	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
-	-	-	-	-	-	-	-	61	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
-	-	-	-	-	-	-	-	-	-	40	623	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of warrant liability
-4,599	-1,871	-5,498	5,352	7,726	-5,687	408	997	-8,424	1,365	-252	-1,746	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for obsolete inventory
-	-	-	-	-	0	295	11	463	319	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Share-Based Payments to Vendors
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	145	-	-	-	-	-	-	-	-	-	-	-	-
Share-Based Payments to Vendors
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	79	78	0	11	58	380	112	0	0	10
Amortization of short-term investment interest income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivable
-16	18	-193	177	-2	-23	-86	51	56	-37	-324	377	-1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inventory
-	-	-	-	-	0	295	11	217	193	-22	104	173	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other assets
-14	12	-10	-41	-114	568	-603	-276	421	-25	-22	256	15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Vendor deposits
-	-	-	-	-	-	-	-	-	-	-410	-12	670	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Right of use assets
-70	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	24	-38	-8	-74	96	13	-13	-31	-51	170	40	3	-2	-2
Security Deposit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-43	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued liabilities
-210	-371	-137	876	81	-249	295	-313	73	-99	431	-326	-114	354	183	831	-737	800	-207	315	-562	-38	631	-20	-13	491	13	-2	35
Accrued bonuses
-849	259	195	238	-574	293	250	196	-542	-1,434	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued interest
20	33	36	42	54	59	56	54	55	56	87	15	70	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other current and long-term liabilities
-72	-	-	-	-5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued interest - related parties
-	-	-	-	-	-	-	-	-	0	0	2	11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other current and long-term liabilities
-	-	-	-	-	-	-	-6	-4	132	68	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-3,774	-3,636	-3,155	-2,592	-3,273	-2,286	-1,398	-2,095	-3,718	-5,695	-1,678	-3,803	-2,129	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Note Receivable from advance to PLx Pharma, Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
CASH FLOWS FROM INVESTING ACTIVITIES
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,940	-5,075	-3,970	-4,389	-3,191	-3,040	-2,852	-2,750	-3,422	-2,251	-857	-842	-232	-261
Purchases of property and equipment
2	96	132	6	6	0	-10	398	267	338	108	18	72	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in investing activities
-2	-96	-132	5	-6	0	10	-398	-267	-338	-108	11,758	-72	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from issuance of convertible Series A preferred stock
-	0	0	0	13,661	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayments of term loan
937	937	937	937	312	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from Short-term Investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,000	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of Short-term Investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,990	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4,009	4,009	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of convertible notes payable
-	-	-	-	-	-	-	-	-	0	0	0	460	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of convertible notes payable - related parties
-	-	-	-	-	-	-	-	-	0	0	0	108	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from Dipexium note
-	-	-	-	-	-	-	-	-	0	0	0	2,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash (used in) provided by financing activities
-937	-775	541	-474	13,349	-	-	-	-	0	7,145	16,698	2,568	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of Common Stock, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	34,455	-	-	-	-
Proceeds from Private Placement Offerings, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	937	1,418	1,350	892
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	34,455	937	1,418	1,350	892
Net Decrease In Cash and Cash Equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,065	-	-	-	-	-	-	-	-	-	-	-	-
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS
-4,714	-4,508	-2,747	-3,062	10,068	-2,286	-1,387	-2,493	-3,986	-6,034	5,358	24,653	366	-	-	-	-	-	-	4,689	-3,040	-2,852	-2,750	-3,422	32,204	79	575	1,117	630
SUPPLEMENTAL INFORMATION
Income taxes
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest
90	113	142	166	177	174	171	166	158	156	39	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NON-CASH INVESTING AND FINANCING TRANSACTIONS
Property and equipment included in accounts payable
-	-	-	-	-	-	-	-	8	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred financing costs included in accounts payable and accrued liabilities
43	-	-	-	44	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Preferred stock beneficial conversion feature and dividends
320	317	311	301	12,820	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Value of common shares issued to vendor for services
-	0	0	22	22	22	22	22	22	22	22	15	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-